Document Detail


BCG effects on telomerase activity in bladder cancer cell lines.
MedLine Citation:
PMID:  12109518     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although intravesical bacillus Calmette-Guerin (BCG) therapy is very effective in the treatment of and prophylaxis against superficial bladder cancer, its exact mechanism of action is not clear. In this study, the effect of BCG on telomerase activity was examined in the T24 and J82 bladder cancer cell lines, the ACHN human renal cell carcinoma cell line, and the PC-3 human prostate cancer cell line.
METHODS: T24 and J82 cells were cocultured with BCG for 5 days. Telomerase activity was measured by telomeric repeat amplification protocol. Cell-cycle phase was determined by FACS analysis.
RESULTS: Telomerase activity in all cell lines provided high absorbance. Telomerase activity in BCG-treated T24 and J82 cells was significantly decreased when compared with that in the nontreated cells. On the other hand, telomerase activity did not change in ACHN and PC-3 cells after they had been cocultured with BCG. In BCG-treated T24 cells and J82 cells, apoptotic cells were markedly increased compared with those in the nontreated cells.
CONCLUSION: These results suggest that the reduction of telomerase activity is related to the mechanism of BCG effects. Possible mechanisms to be considered are either that BCG inhibits telomerase first, or that it induces apoptosis and decreases telomerase activity as a result of this induction.
Authors:
Hideki Saitoh; Kazuyuki Mori; Seiji Kudoh; Hiroyuki Itoh; Nobuyoshi Takahashi; Tadashi Suzuki
Related Documents :
7753808 - Oxidative dna damage and senescence of human diploid fibroblast cells.
19468068 - Induction of alternative lengthening of telomeres-associated pml bodies by p53/p21 requ...
8885238 - Telomerase regulation during entry into the cell cycle in normal human t cells.
18443218 - Telomere dysfunction and cell survival: roles for distinct tin2-containing complexes.
10782338 - The exoskeleton of bacterial cells (the sacculus): still a highly attractive target for...
23504048 - Low-dose sn-38 with paclitaxel induces lethality in human uterine cervical adenocarcino...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical oncology     Volume:  7     ISSN:  1341-9625     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-07-11     Completed Date:  2002-12-19     Revised Date:  2012-12-13    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  165-70     Citation Subset:  IM    
Affiliation:
Department of Urology, Hirosaki University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / pharmacology*
BCG Vaccine / pharmacology*
Carcinoma, Renal Cell / drug therapy,  enzymology
Cell Cycle / drug effects
Cell Survival / drug effects
Humans
Kidney Neoplasms / drug therapy,  enzymology
Male
Prostatic Neoplasms / drug therapy,  enzymology
Telomerase / metabolism*
Tumor Cells, Cultured / drug effects,  enzymology
Urinary Bladder Neoplasms / drug therapy*,  enzymology
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/BCG Vaccine; EC 2.7.7.49/Telomerase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Histological features of hypovascular or avascular renal cell carcinoma: the experience at four univ...
Next Document:  Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver ca...